While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in ...

WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the ...

Wave claimed GSK is walking away from the frontrunning program not because of questions about its potential, but because Wave ...

Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. | Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. GSK has decided not ...

Korro Bio (NASDAQ:KRRO) used its Analyst Day to outline the rationale and development plans for KRRO-121, an RNA-editing ...

The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge ...

Parkinson's disease (PD) is a neurodegenerative disorder in which the α-synuclein protein abnormally aggregates within brain cells, causing neuronal damage. Through international collaboration, ...

ProQR Therapeutics is advancing its Axiomer ADAR-mediated RNA editing pipeline, aiming to file a Clinical Trial Application for its lead program AX-0810, targeting NTCP for cholestatic diseases, by Q2 ...

Parkinson's disease (PD) is a neurodegenerative disorder in which the α-synuclein protein abnormally aggregates within brain cells, causing neuronal damage. Through international collaboration, ...

A research team led by Rice's Yang Gao has uncovered new insights into the molecular mechanisms of ADAR1. ADAR1 converts adenosine to inosine in double-stranded RNA, a process essential for preventing ...